Omics-based large language models: A new engine for drug discovery innovation

Traditional drug discovery suffers from low efficiency and high attrition rates, largely due to the complexity and heterogeneity of human diseases. Omics technologies offer a systems-level perspective for uncovering disease mechanisms and identifying therapeutic targets, but present challenges such as high dimensionality, noise, and heterogeneity. Large language models (LLMs), originally developed for natural language processing, are emerging as powerful tools to address these issues by capturing complex patterns and inferring missing information from large, noisy datasets. We present a three-part framework: (1) Analyzing how LLM architectures and learning paradigms handle challenges specific to genomics, transcriptomics, and proteomics data; (2) Detailing LLM applications in key areas: uncovering disease mechanisms, identifying drug targets, predicting drug response, and simulating cellular behavior; (3) Discussing how insights from omics-integrated LLMs can inform the development of drugs targeting specific pathways, moving beyond single targets towards strategies grounded in underlying disease biology. This framework provides both conceptual insights and practical guidance for leveraging LLMs in omics-driven drug discovery and development.

Authors

Institutions

Publication Details

Journal
Acta Pharmaceutica Sinica B
Published
2025-10-29
DOI
https://doi.org/10.1016/j.apsb.2025.10.034
Primary Topic
Biomedical Text Mining and Ontologies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Omics-based large language models: A new engine for drug discovery innovation

Yuxin Xing, Xiaochu Tong, Xutong Li, Xia Sheng et al.
Acta Pharmaceutica Sinica B
Biomedical Text Mining and Ontologies
article

Omics-based large language models: A new engine for drug discovery innovation

Yuxin Xing, Xiaochu Tong, Xutong Li, Xia Sheng, Mingyue Zheng, Chun Zeng, Xiaoya Zhang, Yuqi Shi
article en

Abstract

Traditional drug discovery suffers from low efficiency and high attrition rates, largely due to the complexity and heterogeneity of human diseases. Omics technologies offer a systems-level perspective for uncovering disease mechanisms and identifying therapeutic targets, but present challenges such as high dimensionality, noise, and heterogeneity. Large language models (LLMs), originally developed for natural language processing, are emerging as powerful tools to address these issues by capturing complex patterns and inferring missing information from large, noisy datasets. We present a three-part framework: (1) Analyzing how LLM architectures and learning paradigms handle challenges specific to genomics, transcriptomics, and proteomics data; (2) Detailing LLM applications in key areas: uncovering disease mechanisms, identifying drug targets, predicting drug response, and simulating cellular behavior; (3) Discussing how insights from omics-integrated LLMs can inform the development of drugs targeting specific pathways, moving beyond single targets towards strategies grounded in underlying disease biology. This framework provides both conceptual insights and practical guidance for leveraging LLMs in omics-driven drug discovery and development.

Acta Pharmaceutica Sinica BVol. 16(1)
Shanghai Institute of Materia Medica (CN), University of Chinese Academy of Sciences (CN)
Openalex Percentile: Top 72%
Biomedical Text Mining and Ontologies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Omics-based large language models: A new engine for drug discovery innovation — Yuxin Xing, Xiaochu Tong, et al. · Acta Pharmaceutica Sinica B (2025) | TGRS Research Map | TGRS